中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2014年
34期
15-16
,共2页
进展性脑卒中%抗血小板聚集%多靶联合治疗
進展性腦卒中%抗血小闆聚集%多靶聯閤治療
진전성뇌졸중%항혈소판취집%다파연합치료
Stroke in progression%Anti-platelet aggregation%Multi-target therapy
目的：探讨和分析进展性脑卒中多靶联合治疗的临床效果与安全性°方法选取该院自2012年11月—2013年10月收治的进展性脑卒中患者共172例，按照随机原则分成观察组和对照组，对照组给予参麦、单唾液酸四己糖神经节苷脂与低分子肝素进行治疗，观察组则在对照组的基础上另外加用药物巴曲酶注射液，然后对比该两组患者的治疗效果和不良临床事件的发生状况°结果经治疗后，观察组患者的总有效率为89.8%，明显高于对照组患者的72.9%，在治疗以后的第11天，观察组血纤维蛋白原(FIB )指标明显低于对照组患者，但是两组间的活化部分凝血酶原时间(APTT)以及凝血酶原时间(PT﹚指标对比，没有明显的差异，该两组患者均没有明显的并发症发生°结论对于进展性脑卒中患者，通过抗凝、降纤及抗血小板聚集等多靶联合治疗，效果明显，且不良临床事件的发生率低，值得临床推广°
目的：探討和分析進展性腦卒中多靶聯閤治療的臨床效果與安全性°方法選取該院自2012年11月—2013年10月收治的進展性腦卒中患者共172例，按照隨機原則分成觀察組和對照組，對照組給予參麥、單唾液痠四己糖神經節苷脂與低分子肝素進行治療，觀察組則在對照組的基礎上另外加用藥物巴麯酶註射液，然後對比該兩組患者的治療效果和不良臨床事件的髮生狀況°結果經治療後，觀察組患者的總有效率為89.8%，明顯高于對照組患者的72.9%，在治療以後的第11天，觀察組血纖維蛋白原(FIB )指標明顯低于對照組患者，但是兩組間的活化部分凝血酶原時間(APTT)以及凝血酶原時間(PT﹚指標對比，沒有明顯的差異，該兩組患者均沒有明顯的併髮癥髮生°結論對于進展性腦卒中患者，通過抗凝、降纖及抗血小闆聚集等多靶聯閤治療，效果明顯，且不良臨床事件的髮生率低，值得臨床推廣°
목적：탐토화분석진전성뇌졸중다파연합치료적림상효과여안전성°방법선취해원자2012년11월—2013년10월수치적진전성뇌졸중환자공172례，안조수궤원칙분성관찰조화대조조，대조조급여삼맥、단타액산사기당신경절감지여저분자간소진행치료，관찰조칙재대조조적기출상령외가용약물파곡매주사액，연후대비해량조환자적치료효과화불량림상사건적발생상황°결과경치료후，관찰조환자적총유효솔위89.8%，명현고우대조조환자적72.9%，재치료이후적제11천，관찰조혈섬유단백원(FIB )지표명현저우대조조환자，단시량조간적활화부분응혈매원시간(APTT)이급응혈매원시간(PT﹚지표대비，몰유명현적차이，해량조환자균몰유명현적병발증발생°결론대우진전성뇌졸중환자，통과항응、강섬급항혈소판취집등다파연합치료，효과명현，차불량림상사건적발생솔저，치득림상추엄°
Objective To investigate and analyze the clinical effect and safety of multi-target therapy for the treatment of stroke in progression. Methods A total of 172 cases with stroke in progression admitted in our hospital from November 2012 to October 2013 were selected and randomly divided into the observation group and the control group. The control group was given Shenmai, Single sialic acid ganglioside four hexose and Low molecular heparin for treatment, and the observation group was given Batroxobin Injection based on the treatment given to the control group. And the treatment effect and incidence of adverse clinical events of the two groups were compared. Results After treatment, the total effective rate of the observation group was 89.8%, significantly higher than 72.9%of the control group. 11 days after treatment, the fibrinogen (FIB) index of the observation group was much lower than that of the control group, while there were no significant differences in activated partial thromboplastin time (APTT) and prothrom_bin time (PT) between the groups. And no significant complications occurred in both groups. Conclusion For patients with stroke in progression, the multi-target therapy, that is, anticoagulation combined with reducing fibrinogen therapy, anti-platelet aggrega_tion and so on has more significant effect with lower incidence of adverse clinical events, which is worth the clinical promotion.
